Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study

Approximately one‐third of patients diagnosed with Hodgkin lymphoma presenting with Stage IV disease do not survive past 5 years. We present updated efficacy and safety analyses in high‐risk patient subgroups, defined by Stage IV disease or International Prognostic Score (IPS) of 4–7, enrolled in th...

全面介紹

Na minha lista:
書目詳細資料
發表在:Hematol Oncol
Main Authors: Hutchings, Martin, Radford, John, Ansell, Stephen M., Illés, Árpád, Sureda, Anna, Connors, Joseph M., Sýkorová, Alice, Shibayama, Hirohiko, Abramson, Jeremy S., Chua, Neil S., Friedberg, Jonathan W., Kořen, Jan, LaCasce, Ann Steward, Molina, Lysiane, Engley, Gerald, Fenton, Keenan, Jolin, Hina, Liu, Rachael, Gautam, Ashish, Gallamini, Andrea
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2021
主題:
Original Research Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8247884/
https://ncbi.nlm.nih.gov/pubmed/33462822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hon.2838
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍